ARS Pharmaceuticals, Inc. SPRY Total debt

Total debt at other companies

Aquestive Therapeutics, Inc.AQST

$64.36M+7.4%

Amneal Pharmaceuticals, Inc.AMRX

$2.57B+18.0%

ViatrisVTRS

$13.63B-7.7%

AMP

Amphastar PharmaceuticalsAMPH

$688.51M+5.0%

Neuropace, Inc.NPCE

$70.46M-3.7%

Eton Pharmaceuticals, Inc.ETON

$31.26M+3.7%

FAQ

What is ARS Pharmaceuticals, Inc.'s total debt?

ARS Pharmaceuticals, Inc. (SPRY) reported total debt of $96.52M in Q1 2026.

How has ARS Pharmaceuticals, Inc.'s total debt changed year-over-year?

ARS Pharmaceuticals, Inc.'s total debt increased by 132121.9% year-over-year, from $73K to $96.52M.

What is the long-term trend for ARS Pharmaceuticals, Inc.'s total debt?

Over 5 years (2020 to 2025), ARS Pharmaceuticals, Inc.'s total debt has grown at a 97.3% compound annual growth rate (CAGR), from $3.22M to $96.37M.

What does total debt mean?

Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.